{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:15:02Z","timestamp":1783955702570,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urolonc.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:21:51Z","timestamp":1737674511000},"page":"397.e9-397.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"W\u00fcrnschimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.01.001_bib0001","unstructured":"Mottet N., van den Bergh R.C.N., Briers E., Bourke L., Cornford P., De Santis M., et al. Wiegel. EAU guidelines on prostate cancer. 2019."},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100575","article-title":"Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.001_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Mandel","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0004","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: an updated network meta-analysis including ARANOTE data","author":"Hoeh","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.001_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.001_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"15","key":"10.1016\/j.urolonc.2025.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0008","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"11","key":"10.1016\/j.urolonc.2025.01.001_bib0009","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.urolonc.2025.01.001_bib0011","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with Enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.01.001_bib0012","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.urolonc.2025.01.001_bib0013","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.001_bib0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/pros.24249","article-title":"Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients","volume":"82","author":"Wenzel","year":"2022","journal-title":"The Prostate"},{"issue":"10","key":"10.1016\/j.urolonc.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.001_bib0016","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101720","article-title":"Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments","volume":"15","author":"Parthipan","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101621","article-title":"Treatment patterns and outcomes in older adults with castration-resistant prostate cancer: analysis of an Australian real-world cohort","volume":"14","author":"Fernando","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0019","unstructured":"Toxicity and response criteria of the Eastern Cooperative Oncology Group - PubMed. Accessed May 13, 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/7165009\/"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/2047-3095.12445","article-title":"Prognostic value of defining characteristics in frail elderly syndrome: hospital readmission and mortality outcomes","volume":"35","author":"Rold\u00e1n-Chicano","year":"2023","journal-title":"Int J Nurs Knowl"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fphys.2017.00603","article-title":"Falls and fall-prevention in older persons: geriatrics meets spaceflight!","volume":"8","author":"Goswami","year":"2017","journal-title":"Front Physiol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.12.005","article-title":"The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer","volume":"14","author":"Kim","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101520","article-title":"Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer","volume":"14","author":"Deol","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1194718","article-title":"The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis","volume":"13","author":"Assayag","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102066","article-title":"Cardiovascular toxicity associated with androgen receptor axis-targeted agents in patients with prostate cancer: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhou","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659135","article-title":"Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies","volume":"11","author":"Wenzel","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.001_bib0027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","article-title":"The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.juro.2014.10.088","article-title":"Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer","volume":"193","author":"Koo","year":"2015","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2025.01.001_bib0029","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/pros.24209","article-title":"The effect of primary urological cancers on survival in men with secondary prostate cancer","volume":"81","author":"Wenzel","year":"2021","journal-title":"The Prostate"},{"key":"10.1016\/j.urolonc.2025.01.001_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754996","article-title":"The effect of 10 most common nonurological primary cancers on survival in men with secondary prostate cancer","volume":"11","author":"Wenzel","year":"2021","journal-title":"Front Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:48Z","timestamp":1762363968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1078143925000018"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}